Publications

A Phase 2 Controlled Study of SB206, a Topical Nitric Oxide-Releasing Drug for Extragenital Wart Treatment

Stephen K. Tyring, Theodore Rosen, Brian Berman, Nathan Stasko, Todd Durham, Tomoko Maeda-Chubachi

Conclusion: Berdazimer Sodium (SB206) plus hydrogel was efficacious and well tolerated in the treatment of EGW/PAW.

Read More

A Phase 2, Controlled, Dose-Ranging Study of SB208, an Investigational Topical Nitric Oxide-Releasing Drug, for the Treatment of Tinea Pedis

Boni E. Elewshi, Leon H. Kircik, Nathan Stasko, Emily de Leon, Carolyn Enloe, Todd Durham, Tomoko Maeda-Chubachi

Conclusion: Topical SB208 was effective and well tolerated in the treatment of tinea pedis.

Read More

Nitric Oxide-Releasing Macromolecule Exhibits Broad-Spectrum Antifungal Activity and Utility as a Topical Treatment for Superficial Fungal Infections

Nathan Stasko, Kimberly McHale, Stanley Hollenbach, Megan Martin, Ryan Doxey

Conclusions: In in vitro studies, Novan demonstrated that nitric oxide-releasing treatments rapidly penetrated the nail plate and eradicated fungal infections, representing promising novel topical therapies for the treatment of onychomycosis and other cutaneous fungal infections.

Read More

Results of a Phase 2 Efficacy and Safety Study with SB204, an Investigational Topical Nitric Oxide-releasing Drug for the Treatment of Acne Vulgaris

Hilary Baldwin, MD; Daisy Blanco, MD; Charles McKeever, MD; Nelly Paz, MD; Ynca Nina Vasquez, MD; John Quiring, PhD; Carolyn Enloe, MPH; Emily de León, MSCR; Nathan Stasko, PhD

Conclusions: When compared to vehicle, both SB204 1% and SB204 4% significantly decreased the percentage of noninflammatory lesions and SB204 4% also significantly decreased the percentage of inflammatory lesions in subjects with acne vulgaris treated for 12 weeks. Treatment with SB204 1% and SB204 4% was safe and well-tolerated.

Read More

Results of a Phase 2, Randomized,Vehicle-Controlled Study Evaluating the Efficacy,Tolerability, and Safety of Daily or Twice Daily SB204 for the Treatment of Acne Vulgaris

Lawrence F. Eichenfield, MD; Linda Stein Gold, MD; Walter K. Nahm, MD, PhD; Fran E. Cook-Bolden, MD; David M. Pariser, MD

Conclusions: When compared to vehicle, SB204 2% and SB204 4% significantly decreased the absolute inflammatory lesion count and SB204 4% once-daily also significantly decreased the absolute non-inflammatory lesion count in subjects with acne vulgaris treated for 12 weeks. Treatment with SB204 2% and 4% was found to be safe and well tolerated.

Read More

Close
Close